223 related articles for article (PubMed ID: 29329598)
1. Treatment outcome of anti-angiogenesis through VEGF-pathway in the management of gastric cancer: a systematic review of phase II and III clinical trials.
Mawalla B; Yuan X; Luo X; Chalya PL
BMC Res Notes; 2018 Jan; 11(1):21. PubMed ID: 29329598
[TBL] [Abstract][Full Text] [Related]
2. Controlling angiogenesis in gastric cancer: A systematic review of anti-angiogenic trials.
Shan F; Miao R; Xue K; Li Z; Li Z; Bu Z; Wu A; Zhang L; Wu X; Zong X; Wang X; Li S; Ji X; Jia Z; Li Z; Ji J
Cancer Lett; 2016 Oct; 380(2):598-607. PubMed ID: 26724681
[TBL] [Abstract][Full Text] [Related]
3. Anti-angiogenic therapies for gastric cancer.
Hironaka S
Asia Pac J Clin Oncol; 2019 Aug; 15(4):208-217. PubMed ID: 31111678
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor a inhibition in gastric cancer.
Park DJ; Thomas NJ; Yoon C; Yoon SS
Gastric Cancer; 2015 Jan; 18(1):33-42. PubMed ID: 24993497
[TBL] [Abstract][Full Text] [Related]
5. Apatinib for the treatment of gastric cancer.
Geng R; Li J
Expert Opin Pharmacother; 2015 Jan; 16(1):117-22. PubMed ID: 25420417
[TBL] [Abstract][Full Text] [Related]
6. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
Fuchs CS; Tomasek J; Yong CJ; Dumitru F; Passalacqua R; Goswami C; Safran H; Dos Santos LV; Aprile G; Ferry DR; Melichar B; Tehfe M; Topuzov E; Zalcberg JR; Chau I; Campbell W; Sivanandan C; Pikiel J; Koshiji M; Hsu Y; Liepa AM; Gao L; Schwartz JD; Tabernero J;
Lancet; 2014 Jan; 383(9911):31-39. PubMed ID: 24094768
[TBL] [Abstract][Full Text] [Related]
7. Lessons from phase III clinical trials on anti-VEGF therapy for cancer.
Jain RK; Duda DG; Clark JW; Loeffler JS
Nat Clin Pract Oncol; 2006 Jan; 3(1):24-40. PubMed ID: 16407877
[TBL] [Abstract][Full Text] [Related]
8. Update on Biomarkers in Development of Anti-angiogenic Drugs in Gastric Cancer.
Jia S; Cai J
Anticancer Res; 2016 Mar; 36(3):1111-8. PubMed ID: 26977006
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer.
Gambardella V; Tarazona N; Cejalvo JM; Roselló S; Cervantes A
Expert Opin Drug Metab Toxicol; 2016; 12(4):449-56. PubMed ID: 26895445
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor (VEGF) inhibition by small molecules.
Ahmed SI; Thomas AL; Steward WP
J Chemother; 2004 Nov; 16 Suppl 4():59-63. PubMed ID: 15688612
[TBL] [Abstract][Full Text] [Related]
11. Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer.
Roviello G; Ravelli A; Polom K; Petrioli R; Marano L; Marrelli D; Roviello F; Generali D
Cancer Lett; 2016 Mar; 372(2):187-91. PubMed ID: 26797419
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
13. A systematic review and meta-analysis on the effect of angiogenesis blockade for the treatment of gastric cancer.
Bai ZG; Zhang ZT
Onco Targets Ther; 2018; 11():7077-7087. PubMed ID: 30410364
[TBL] [Abstract][Full Text] [Related]
14. Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer.
Kawakami H; Okamoto I; Hayashi H; Taguri M; Morita S; Nakagawa K
Eur J Cancer; 2013 Sep; 49(14):3003-9. PubMed ID: 23791540
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.
Van Cutsem E; de Haas S; Kang YK; Ohtsu A; Tebbutt NC; Ming Xu J; Peng Yong W; Langer B; Delmar P; Scherer SJ; Shah MA
J Clin Oncol; 2012 Jun; 30(17):2119-27. PubMed ID: 22565005
[TBL] [Abstract][Full Text] [Related]
16. Ramucirumab: A Review in Advanced Gastric Cancer.
Greig SL; Keating GM
BioDrugs; 2015 Oct; 29(5):341-51. PubMed ID: 26341713
[TBL] [Abstract][Full Text] [Related]
17. The safety and efficacy of ramucirumab in combination with paclitaxel for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma.
Garrido M
Expert Rev Anticancer Ther; 2016 Oct; 16(10):1005-10. PubMed ID: 27582051
[TBL] [Abstract][Full Text] [Related]
18. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer.
Krupitskaya Y; Wakelee HA
Curr Opin Investig Drugs; 2009 Jun; 10(6):597-605. PubMed ID: 19513949
[TBL] [Abstract][Full Text] [Related]
19. Ramucirumab for gastric cancer.
Shitara K; Ohtsu A
Expert Rev Gastroenterol Hepatol; 2015 Feb; 9(2):133-9. PubMed ID: 25431958
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy for previously treated advanced gastric cancer: A systematic review and network meta-analysis.
Cheng J; Cai M; Shuai X; Gao J; Wang G; Tao K
Crit Rev Oncol Hematol; 2019 Nov; 143():27-45. PubMed ID: 31449984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]